Products - Oesophageal cancer | Topic | NICE

Showing 8 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC